Real-time reactions to earnings, macro events and market moves — what actually happened, what the numbers show, and what we’re doing about it in our own positions. Not price predictions, a working read on the stocks and events moving the market this week.
Emerson Electric trades at 32.8 times trailing earnings, 55% above its own five-year average of 21.2 and only slightly above its industry at 30.2. Operating income jumped 32% on 3% revenue growth. Is that enough…
In 2015 Kinder Morgan paid $4.22B in dividends on $1.42B of free cash flow. In 2025 it paid $2.60B on $2.89B. The dividend has caught up, but cover fell from 1.75x in 2021 to 1.11x…
Dell booked $90.8 billion of revenue in half a year, 80% of all of fiscal 2026. But each extra revenue dollar brought about 8 cents of gross profit. We test the AI server story against…
Intuitive Surgical is 35% below its high and at the 3rd percentile of its own five-year P/E range, yet it still costs 45 times earnings. We check the income statement, the recurring revenue mix and…
Capital One’s quant score fell from 53 to 19 in a week and stayed a D, while 89% of analysts say buy. Which reading of a 37% revenue jump and a 48% profit drop is…
HPE turned $34.3 billion of fiscal 2025 revenue into about 0.17 cents of profit per dollar, yet the stock sits 4.9% below its high. We test what the Juniper deal must deliver: revenue, margins and…
Blackstone paid $3.30 a share in 2022, then $1.56 in 2023. Its dividend follows earnings, with a lag. We set the payment history against diluted EPS, test the 2.7% verifiable yield, and name the November…
General Motors trades at 36.7 times trailing earnings and 7.1 times forward earnings. One $3.42 loss quarter drives the first, and the second needs about $10 billion of profit GM has never earned in the…
Vertex’s cystic fibrosis drugs still made 96 cents of each segment revenue dollar last quarter, against 3.8 cents for Casgevy and Journavx. We test the title’s claim here and name the numbers that would confirm…
Bristol-Myers pays a 3.98% yield, but Eliquis and Opdivo made 54 cents of every named-product dollar last quarter. We test how much of that risk the price already discounts, and which quarterly number would start…